Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1812
Dell'Erba G. 1, Di Girolamo F. 2, Losi T. 2, Vizza C. D. 2
1 ASL Roma H, Distretto Sociosanitario, Genzano (Roma);
2 Università degli Studi di Roma «La Sapienza» - Roma , Dipartimento di Scienze Cardiovascolari e Respiratorie
After a description of the asthenic syndrome and some observations on its frequency in the population, the authors describe the rationale for the therapeutical use of different categories of substances with antiasthenic properties. Among these, special attention is given to Arginine Aspartate, a dipeptide very used in the treatment of mental and physical asthenia. At first, the pharmacokinetic characteristics of the substance, studied in trials in animals and in healthy volunteers, are reviewed. Afterwards, some experimental data on the pharmacodynamics of Arginine Aspartate are presented, selecting these documenting the biochemical mechanism of action supporting the antiasthenic effect of the substance. The last part of the review is devoted to the clinical documentation and has been based on the most recent studies carried out on controlled experimental models, randomized, double blind and with acceptable statistical evaluation of results. On the basis of the data examined and of personal experiences, the conclusion is drawn that Arginine Aspartate has a clear therapeutic properties in the treatment of asthenic conditions.